Comparative Pharmacology
Head-to-head clinical analysis: COMPRO versus TIGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPRO versus TIGAN.
COMPRO vs TIGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prochlorperazine is a phenothiazine antipsychotic that primarily acts as a dopamine D2 receptor antagonist, with additional antagonism at D3, 5-HT2A, alpha1-adrenergic, and histamine H1 receptors. It also has antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
5 to 10 mg intramuscularly every 3 to 4 hours as needed; or 5 to 10 mg intravenously at a rate not exceeding 5 mg per minute; or 10 mg orally every 6 to 8 hours; maximum daily dose 40 mg.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults (prolonged in hepatic impairment, cirrhosis up to 10-12 hours; neonates up to 24 hours).
12-15 hours; may be prolonged in hepatic impairment.
Renal: 70-80% as glucuronide and sulfate conjugates; biliary/fecal: <10% unchanged; <5% as unchanged drug in urine.
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Category C
Category C
Antiemetic
Antiemetic